glaxo facing calls to spin off its consumer health business. look at the industry in its entirety, where is it heading? ess is more or bulk is best? kristen: there seems to be a dichotomy. you do see companies like astrazeneca shedding assets and trying to focus more on its cancer pipeline. you see companies like glaxo saying, you know, we want to have a kristen: there seems to be a co business. it's been a great, you know, cushion for us when the drug business has been difficult. and then you see companies like, for example, bristol-myers in the u.s., which has been very, very focused on cancer lately. they actually sold off some h.i.v. medicines so they could focus more on their cancer pipeline. there's a split in the industry. if you look at the news today, you can see the perils. mark: where is sanofi exceling? i know it got a lift from the early flu vaccine, the diabetes franchise, that obviously fell similar to novo nortis. kristen: well, vaccines, as you said, there was a very pleasant increase in the vaccines business. but they've also

ibm is also building on existing partnerships with apple, glaxo smith kplin decline, 1-800 flowers andn airlines. >> they are tapping into the insights of what consumers are really feeling in the moment when the first symptom strikes. >> and if you come to us today and let's say you're a previous customer of mine, looking to send something for a birthday today, we look in our database and realize it's your mother-in-law's birthday next week, we will remind you. >> watson is already making major leaps in medicine using big data analytics to boost personalize cancer therapies. beyond the enterprise applications, developers and designers are experimenting with watson. like this cognitive beer stabbed that chooses a brew based on your personality. and feedback on social media. >> it gives us a platform and i think this can only help excite our customers to really respond to their wants and needs. and i think what was exciting about watson, we can feed in information and really get a read on the emotional response of our consumer. so, yes, i think it only enhances designers. >> reporter: ib

. >> glaxo smithkline, i hear they're investing a lot in bio electronics at the moment. they did this joint venture with what used to be google life sciences. is this an weaarea -- is that t medicine of tomorrow? >> i think pharma r&d and life sciences is so risky you never know where the next thing is coming from. it's exciting to see collaborations with some big names and some less big names. they announced something about next generation antibiotics with a small biotech that doesn't have a great profile and i already forgot the name. but it's incredibly exciting and offers great potential. >> brian mcgee, engagement manag manager, thank you very much. it's a whole new world. >> yeah. >> all technology. let's get on with earnings. renau renault has seen strong demand in europe. shares are up by 1.3%. >>> rival peugeot saw revenue fall by 5%. new car sales dropping by 17% in china and 4% in europe. the second largest carmaker said it saw overall car market growth of 6% in 2016 in line with other automakers and analysts. >>> let's talk luxury. kering reporting a 10% jump

the wind behind the back on the collapse of the british popped, and most people think glaxo is a u.s.ompany. it's british. it has a huge advantage now in terms of selling into our domestic market. you have to back up the truck on this one. i think institutional dollars will flow into this sector as we rebalance in q4. i'm trying to figure out where is that money going to go looking at what we're all concerned about in volatility, political environment, and where you can get any kind of performance next year. i'm not liking energy because the balance sheets are really deteriorating. i don't like much more up side in tech right here. i think that we're up at the top of the stretch range on pes. but i look at these pummeled sectors. phrma, by he owe teiotebiotech. ihi, it's been killed. hillary is doing a hell of a good job at creating value for investors. >> the other stocks sort of in this universe we should talk about, bristol-myers. lowest level since october of 2014. gilyard, lowest since april of 2014. cigna, lowest since march of 2015. >> gilyard, right now they're a one project c

program, on this glaxo-smith-kline ceo plus bank of america's bond market joins us to reveal the -- aso the cache open, we are one hour and four minutes away. futures off the low. this is bloomberg. ♪ alix: this is bloomberg daybreak. here is what you need to know. troubles, shares fell after falling smartphone prices and it is supporting holiday forecast. donald trump has a two-point lead ahead of hillary clinton in florida. when it comes to the markets, it is a sound of silence. will slowing to a crawl, ahead of the u.s. election. butch a bank is looking for alternatives to cash bonuses. to boost capital and shore up investor confidence. here is how the market is capturing some of those stories. off the lows on futures, the dow up by about eight points. an upside surprise on boeing helping to lift the dow. europe down by one full percentage point on the ftse. globally on offer, yields up to basis points. as more doubtsr emerge over the opec agreement on whether they can actually executed. -- execute it. a lot of earnings coming through on both sides of the atlantic. third-quarter ear